Speedie S M, McNally D, Skarupa S, Michocki R, Rudo C, Metge C, Palumbo F, Knapp D
Center on Drugs and Public Policy, University of Maryland, Baltimore Graduate School.
Proc Annu Symp Comput Appl Med Care. 1992:621-5.
DUR is a process of problem detection and intervention designed to improve the quality and economy of drug prescribing. Retrospective DUR attempts to detect and address patterns of prescribing that might be indicative of inappropriate therapy. When the process is extended to a largely ambulatory population such as Medicaid beneficiaries, a number of complications are introduced due to the large numbers of patients and sparsity of data. In order to examine the impact of implementing a Medicaid DUR program, we developed a system that would apply screening criteria to prescription claims. It has been used to screen prescribing of groups of two antihypertensive drugs in the 1990 Maryland Medicaid population for 177,409 Medicaid eligible individuals. Potentially significant problems were detected with respect to dosing, duplication of therapeutic agents and drug interactions. The system represents, we believe, a significant improvement in the ability to detect and report prescribing decisions by increasing the specificity of the detection system. By the application of this system to a set of real-world data, we have demonstrated that it is feasible to implement such a system and derive results that are potentially useful in reducing the incidence of inappropriate physician decision-making.
药物利用审查(DUR)是一个旨在提高药物处方质量和经济性的问题检测与干预过程。回顾性药物利用审查试图检测并解决可能表明治疗不当的处方模式。当该过程扩展到如医疗补助受益人群这样的大量门诊患者时,由于患者数量众多且数据稀疏,会引入一些复杂问题。为了研究实施医疗补助药物利用审查计划的影响,我们开发了一个将筛选标准应用于处方索赔的系统。该系统已用于对1990年马里兰州医疗补助人群中177,409名符合医疗补助条件的个体的两组抗高血压药物处方进行筛选。在剂量、治疗药物重复和药物相互作用方面发现了潜在的重大问题。我们认为,该系统通过提高检测系统的特异性,在检测和报告处方决策能力方面有了显著改进。通过将该系统应用于一组实际数据,我们证明了实施这样一个系统并得出可能有助于减少不当医生决策发生率的结果是可行的。